Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label extension of enzalutamide for prostate cancer
NL-OMON53607Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC), sponsored by Astellas Pharma. Primary endpoints: Long-term safety of enzalutamide and Continuation of prior treatment regimen until discontinuation criteria are met. Started May 2023; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NL-OMON53607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53607.